3-point major cardiovascular event outcome for patients with T2D treated with dipeptidyl peptidase-4 inhibitor or glucagon-like peptide-1 receptor agonist in addition to metformin monotherapy

BACKGROUND: The global incidence of type 2 diabetes (T2D) continues to increase annually, and persons with T2D typically require regular changes in pharmacologic invention for achieving glycemic targets. Healthcare providers must consider multiple factors when selecting a 2nd line. This retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: El Sanadi, Caroline E., Ji, Xinge, Kattan, Michael W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723528/
https://www.ncbi.nlm.nih.gov/pubmed/33313090
http://dx.doi.org/10.21037/atm-20-4063

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723528/
https://www.ncbi.nlm.nih.gov/pubmed/33313090
http://dx.doi.org/10.21037/atm-20-4063

Ejemplares similares